These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

53 related articles for article (PubMed ID: 8548749)

  • 1. B7.1 expression on tumor cells circumvents the need of professional antigen presentation for in vitro propagation of cytotoxic T cell lines.
    Iezzi G; Protti MP; Rugarli C; Bellone M
    Cancer Res; 1996 Jan; 56(1):11-5. PubMed ID: 8548749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction and large-scale expansion of CD8+ tumor specific cytotoxic T lymphocytes from peripheral blood lymphocytes by in vitro stimulation with CD80-transfected autologous melanoma cells.
    Mackensen A; Wittnebel S; Veelken H; Noppen C; Spagnoli GC; Lindermann A
    Eur Cytokine Netw; 1999 Sep; 10(3):329-36. PubMed ID: 10477389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The infection of human dendritic cells with recombinant avipox vectors expressing a costimulatory molecule transgene (CD80) to enhance the activation of antigen-specific cytolytic T cells.
    Tsang KY; Zhu M; Even J; Gulley J; Arlen P; Schlom J
    Cancer Res; 2001 Oct; 61(20):7568-76. PubMed ID: 11606396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. B7-1 and 4-1BB ligand expression on a myeloma cell line makes it possible to expand autologous tumor-specific cytotoxic T cells in vitro.
    Lu ZY; Condomines M; Tarte K; Nadal L; Delteil MC; Rossi JF; Ferrand C; Klein B
    Exp Hematol; 2007 Mar; 35(3):443-53. PubMed ID: 17309825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetically engineered fibroblasts with antigen-presenting capability: efficient induction of an antigen-specific cytotoxic T-lymphocyte response and protection against tumor development in vivo.
    Kim TS; Chung SW; Kim SH; Kang BY; Hwang SY; Lee JW
    Cancer Gene Ther; 2000 Jun; 7(6):861-9. PubMed ID: 10880016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of melanoma antigen-specific cytotoxic T lymphocytes in vitro by stimulation with B7-expressing human melanoma cell lines.
    Fenton RG; Turcovski-Corrales SM; Taub DD
    J Immunother; 1998 Mar; 21(2):95-108. PubMed ID: 9551360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD28, IL-2-independent costimulatory pathways for CD8 T lymphocyte activation.
    Sepulveda H; Cerwenka A; Morgan T; Dutton RW
    J Immunol; 1999 Aug; 163(3):1133-42. PubMed ID: 10415007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A triad of costimulatory molecules synergize to amplify T-cell activation.
    Hodge JW; Sabzevari H; Yafal AG; Gritz L; Lorenz MG; Schlom J
    Cancer Res; 1999 Nov; 59(22):5800-7. PubMed ID: 10582702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induced expression of B7-1 on myeloma cells following retroviral gene transfer results in tumor-specific recognition by cytotoxic T cells.
    Tarte K; Zhang XG; Legouffe E; Hertog C; Mehtali M; Rossi JF; Klein B
    J Immunol; 1999 Jul; 163(1):514-24. PubMed ID: 10384156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical grade expansion of CD45RA, CD45RO, and CD62L-positive T-cell lines from HLA-compatible donors: high cytotoxic potential against AML and ALL cells.
    Barbui AM; Borleri G; Conti E; Ciocca A; Salvi A; Micò C; Introna M; Rambaldi A
    Exp Hematol; 2006 Apr; 34(4):475-85. PubMed ID: 16569594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective antigen presenting activity of cortical thymic epithelial cells against CD4+ T cells associated with both lack of costimulatory molecules and inefficient presentation of MHC-peptide ligands.
    Kaneda R; Iwabuchi K; Kasai M; Murakami M; Uede T; Onoé K
    Cell Immunol; 1997 Nov; 181(2):163-71. PubMed ID: 9398403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B7 costimulatory molecules from malignant cells in patients with b-cell chronic lymphoproliferative disorders trigger t-cell proliferation.
    Trentin L; Perin A; Siviero M; Piazza F; Facco M; Gurrieri C; Galvan S; Adami F; Agostini C; Pizzolo G; Zambello R; Semenzato G
    Cancer; 2000 Sep; 89(6):1259-68. PubMed ID: 11002221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. On the site and mode of antigen presentation for the initiation of clonal expansion of CD8 T cells specific for a natural tumor antigen.
    Bai XF; Gao JX; Liu J; Wen J; Zheng P; Liu Y
    Cancer Res; 2001 Sep; 61(18):6860-7. PubMed ID: 11559562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene transfer of the CD80 costimulatory molecule into ocular melanoma cells using a novel episomal vector.
    Uno T; Chen PW; Murray TG; Podack ER; Ksander BR
    Invest Ophthalmol Vis Sci; 1997 Nov; 38(12):2531-9. PubMed ID: 9375572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced activation of human T cells via avipox vector-mediated hyperexpression of a triad of costimulatory molecules in human dendritic cells.
    Zhu M; Terasawa H; Gulley J; Panicali D; Arlen P; Schlom J; Tsang KY
    Cancer Res; 2001 May; 61(9):3725-34. PubMed ID: 11325845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The capacity of the natural ligands for CD28 to drive IL-4 expression in naïve and antigen-primed CD4+ and CD8+ T cells.
    Bian Y; Hiraoka S; Tomura M; Zhou XY; Yashiro-Ohtani Y; Mori Y; Shimizu J; Ono S; Dunussi-Joannopoulos K; Wolf S; Fujiwara H
    Int Immunol; 2005 Jan; 17(1):73-83. PubMed ID: 15569772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complete rejection of a T-cell lymphoma due to synergism of T-cell receptor costimulatory molecules, CD80, CD40L, and CD40.
    Ruybal P; Gravisaco MJ; Barcala V; Escalada A; Di Sciullo P; Waldner C; Mongini C
    Vaccine; 2008 Jan; 26(5):697-705. PubMed ID: 18155328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of anergy in CD8 T cells by B cell presentation of antigen.
    Höllsberg P; Batra V; Dressel A; Hafler DA
    J Immunol; 1996 Dec; 157(12):5269-76. PubMed ID: 8955172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD80-transfected human breast and ovarian tumor cell lines: improved immunogenicity and induction of cytolytic CD8+ T lymphocytes.
    Gückel B; Lindauer M; Rudy W; Habicht A; Siebels M; Kaul S; Bastert G; Meuer SC; Moebius U
    Cytokines Mol Ther; 1995 Sep; 1(3):211-21. PubMed ID: 9384677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. B7.1 is a quantitatively stronger costimulus than B7.2 in the activation of naive CD8+ TCR-transgenic T cells.
    Fields PE; Finch RJ; Gray GS; Zollner R; Thomas JL; Sturmhoefel K; Lee K; Wolf S; Gajewski TF; Fitch FW
    J Immunol; 1998 Nov; 161(10):5268-75. PubMed ID: 9820499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.